Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective (RACSMEI)

January 14, 2026 updated by: Institut Pasteur du Cambodge

RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.

RACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.

Mathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.

Study Overview

Status

Recruiting

Conditions

Detailed Description

RACSMEI is a nationwide, One Health, multi-pathogen initiative designed to generate integrated evidence for public-health decision-making in Cambodia. Beyond producing epidemiological findings, the project will establish a structured biobank and curated datasets intended to support long-term collaborative research, knowledge sharing, and evidence-informed policy. The program includes capacity building and technology transfer to strengthen national institutions and foster regional scientific leadership and international collaboration. Engagement with communities and national stakeholders is planned to facilitate future studies and promote the uptake of results in practice. Overall, RACSMEI aims to provide a scalable model for integrated infectious-disease assessment in low- and middle-income settings, creating durable infrastructure, partnerships, and decision-support resources that can be used beyond the project period.

Study Type

Observational

Enrollment (Estimated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Cambodia
    • Phnom Penh
      • Phnom Penh, Phnom Penh, Cambodia, 12201
        • Recruiting
        • Institut Pasteur du Cambodge
        • Contact:
        • Contact:
        • Principal Investigator:
          • Claude Flamand, Ph.D
        • Sub-Investigator:
          • Tephanie Sieng, Ph.D
        • Sub-Investigator:
          • Erik Karlsson, Ph.D
        • Sub-Investigator:
          • Sokleaph CHENG, Ph.D
        • Sub-Investigator:
          • Sébastien Boyer, Ph.D

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

The study population comprises approximately 10,000 participants aged 2 to 75 years, drawn from 4,160 households across Cambodia's 25 provinces. Households will be randomly selected from 104 villages to ensure a nationally representative sample that reflects the country's diverse geographic and demographic characteristics. Participants will provide detailed socio-demographic information, enabling post-stratification weighted analysis of the sample's structure by sex, age, and geographic area to facilitate the extrapolation of findings to the entire population, ensuring that the study's conclusions are broadly applicable.

Description

Inclusion Criteria:

  • Residency in the village for more than 6 months;
  • Age between 2 and 75 years old at the time of inclusion;
  • For adults: provision of written consent;
  • For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;

Exclusion Criteria:

  • Unable to understand or consent;
  • Under guardianship or deprived of liberty;
  • Medical conditions that impede survey participation;
  • Refusal to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Human Community Cohort (National Population Sample)
Probability-based, multi-stage population sample of ~10,000 participants (2-75 years old) recruited across urban and rural communities nationwide. Data include standardized questionnaires (demography, health conditions, mobility, animal contact, healthcare access) and serum biospecimens for multiplex serology;

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Seroprevalence of antibodies against an established panel of priority pathogens in the surveyed human populations:
Time Frame: At the time of blood sampling during household visits, over the inclusion period from December 2025 to April 2026.
The proportion of sampled individuals with detectable antibodies against this priority panel of pathogens, measured using multiplex serological assays.
At the time of blood sampling during household visits, over the inclusion period from December 2025 to April 2026.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut Pasteur du Cambodge

Collaborators

Institut Pasteur
Malaria Consortium
UMR ASTRE (CIRAD)
Ministry of Agriculture, Forestry and Fisheries Cambodia
CDC - Ministry of Health of Cambodia

Investigators

  • Principal Investigator: Claude Flamand, Ph.D., Institut Pasteur du Cambodge

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 18, 2025

Primary Completion (Estimated)

April 16, 2026

Study Completion (Estimated)

September 30, 2027

Study Registration Dates

First Submitted

January 14, 2026

First Submitted That Met QC Criteria

January 14, 2026

First Posted (Actual)

January 22, 2026

Study Record Updates

Last Update Posted (Actual)

January 22, 2026

Last Update Submitted That Met QC Criteria

January 14, 2026

Last Verified

January 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IPasteurCambodge
  • 312353/Z/24/Z (Other Grant/Funding Number: Wellcome Trust)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Japanese Encephalitis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe